Zoetis’ second quarter saw revenue and adjusted earnings surpass Wall Street expectations, but the market responded ...

Shares of Zoetis have been roughly average performers over the past decade. The shares seem appealingly valued at recent ...

Zoetis stock reversed Tuesday, sinking into the red, despite beating second-quarter expectations as Librela sales continued ...

Q2 2025 Management View Kristin C. Peck, CEO, reported "strong broad-based 8% organic operational revenue growth" and noted ...

The reality is that people and animals will always need medicine, treatments, and other products to live long and comfortable ...

Animal health firm Zoetis Inc. (NYSE:ZTS) on Tuesday reported a second-quarter 2025 adjusted earnings per share of $1.76, up ...

From supporting identification of certain cell characteristics to complementing clinical expertise with remote pathologist ...

David Rolfe (Trades, Portfolio) recently submitted the 13F filing for the second quarter of 2025, providing insights int ...

Zoetis Inc - Ordinary Shares - Class A News 7 Agriculture Stocks and ETFs to Buy Demand for food and agriculture products is high and growing fast. Here are 7 investments to buy now.

Zoetis Inc. closed 25.61% short of its 52-week high of $200.33, which the company reached on September 19th.

Zoetis's leadership, scale, and innovation position it well against new competitors. Click here to read more about ZTS stock and why it is a Buy.

Zoetis, a leading animal health company, has shown impressive growth with a 17.55% CAGR since its IPO. Read why I rate ZTS stock a Buy now.